Cardiovascular interactions between losartan and fructose in mice

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 1, 2010, Pages 68-77

  Senador, Danielle ^a   Key, Mary ^a   Brosnihan, K Bridget ^b   Irigoyen, Maria Claudia ^c   Elased, Khalid M ^a   Morris, Mariana ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin; Autonomic nervous system; Blood pressure; Fructose; Glucose tolerance; Losartan; Metabolism; Mice; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; FRUCTOSE; INSULIN; LOSARTAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE VARIABILITY; CARBOHYDRATE DIET; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FOOD DRUG INTERACTION; HEART RATE; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHAM FEEDING; SPECTROSCOPY; TELEMETRY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOTTING, WESTERN; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CHOLESTEROL; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FRUCTOSE; HEART RATE; INSULIN; KIDNEY; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 76649111025     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409351409     Document Type: Article

References (51)

1. Brown CM, Dulloo AG, Montani JP Sugary drinks in the pathogenesis of obesity and cardiovascular diseases. Int J Obes (Lond). 2008 ; 32 (suppl 6). S28 - S34.
2. Johnson RJ, Segal MS, Sautin Y., et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007 ; 86 (4). 899-906.
3. Sowers JR Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004 ; 286 (5). H1597 - H1602.
4. Cooper ME The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004 ; 17 (11 pt 2). 16S - 20S.
5. De AK, Irigoyen MC, Morris M. Diabetes and cardiovascular autonomic dysfunction: application of animal models. Auton Neurosci. 2009 ; 145 (1-2). 3-10.
6. Moan A., Hoieggen A., Seljeflot I., Risanger T., Arnesen H., Kjeldsen SE The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens. 1996 ; 14 (9). 1093-1097.
7. Brown CM, Dulloo AG, Yepuri G., Montani JP Fructose ingestion acutely elevates blood pressure in healthy young humans. Am J Physiol Regul Integr Comp Physiol. 2008 ; 294 (3). R730 - R737.
8. Farah V., Elased KM, Chen Y., et al. Nocturnal hypertension in mice consuming a high fructose diet. Auton Neurosci. 2006 ; 130 (1-2). 41-50.
9. Ziegler D. Diabetic autonomic neuropathy. Cardiac sympathetic dysinnervation, QT interval prolongation, and mortality. Clin Auton Res. 2002 ; 12 (5). 349-352.
10. Dai S., Todd ME, Lee S., McNeill JH Fructose loading induces cardiovascular and metabolic changes in nondiabetic and diabetic rats. Can J Physiol Pharmacol. 1994 ; 72 (7). 771-781.
11. Delbosc S., Paizanis E., Magous R., et al. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis. 2005 ; 179 (1). 43-49.
12. Hwang IS, Ho H., Hoffman BB, Reaven GM Fructose-induced insulin resistance and hypertension in rats. Hypertension. 1987 ; 10 (5). 512-516.
13. Shinozaki K., Ayajiki K., Nishio Y., Sugaya T., Kashiwagi A., Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension. 2004 ; 43 (2). 255-262.
14. Oda T., Hirata M., Oshida Y., Han YQ, Koshinaka K., Sato Y. Effect of imidapril, an angiotensin-converting enzyme inhibitor, on fructose-induced insulin resistance in rats. Endocr J. 2004 ; 51 (1). 69-74.
15. Farah V., Elased KM, Morris M. Genetic and dietary interactions: role of angiotensin AT1a receptors in response to a high-fructose diet. Am J Physiol Heart Circ Physiol. 2007 ; 293 (2). H1083 - H1089.
16. Ferrario CM, Chappell MC Novel angiotensin peptides. Cell Mol Life Sci. 2004 ; 61 (21). 2720-2727.
17. Elased KM, Cunha TS, Marcondes FK, Morris M. Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice. Exp Physiol. 2008 ; 93 (5). 665-675.
18. Tikellis C., Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003 ; 41 (3). 392-397.
19. Wysocki J., Ye M., Soler MJ, et al. ACE and ACE2 activity in diabetic mice. Diabetes. 2006 ; 55 (7). 2132-2139.
20. Ye M., Wysocki J., William J., Soler MJ, Cokic I., Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006 ; 17 (11). 3067-3075.
21. Ferrario CM, Jessup J., Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005 ; 111 (20). 2605-2010.
22. Ye M., Wysocki J., Naaz P., Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination ? Hypertension. 2004 ; 43 (5). 1120-1125.
23. Senador D., Kanakamedala K., Irigoyen MC, Morris M., Elased KM Cardiovascular and autonomic phenotype of db/db diabetic mice. Exp Physiol. 2009 ; 94 (6). 648-658.
24. Tikellis C., Bialkowski K., Pete J., et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes. 2008 ; 57 (4). 1018-1025.
25. Wichi RB, Farah V., Chen Y., Irigoyen MC, Morris M. Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2007 ; 292 (3). R1184 - R1189.
26. Parati G., Pomidossi G., Albini F., Malaspina D., Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens. 1987 ; 5 (1). 93-98.
27. Senanayake PD, Moriguchi A., Kumagai H., Ganten D., Ferrario CM, Brosnihan KB Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides. 1994 ; 15 (5). 919-926.
28. Elased KM, Cool DR, Morris M. Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity 1. Hypertension. 2005 ; 46 (4). 953-959.
29. Vickers C., Hales P., Kaushik V., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002 ; 277 (17). 14838-14843.
30. Lindholm LH, Ibsen H., Borch-Johnsen K., et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002 ; 20 (9). 1879-1886.
31. Amazonas RB, Lopes De Faria JB Effects of tight blood pressure control on glomerular hypertrophy in a model of genetic hypertension and experimental diabetes mellitus. Life Sci. 2006 ; 79 (22). 2135-2143.
32. Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng WT, Chu CH Functional interaction of AT1 and AT2 receptors in fructose-induced insulin resistance and hypertension in rats. Metabolism. 2005 ; 54 (2). 157-164.
33. Shimamura T., Iwasaki T., Hayasaki-Kajiwara Y., Naya N., Nakajima M. Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP. Clin Exp Hypertens. 2002 ; 24 (3). 187-205.
34. Iyer SN, Katovich MJ Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens. 1996 ; 9 (7). 662-668.
35. Zhang HJ, Zhou F., Ji BP, et al. Effects of fructose and/or fat in the diet on developing the type 2 diabetic-like syndrome in CD-1 mice. Horm Metab Res. 2009 ; 41 (1). 40-45.
36. Messier C., Whately K., Liang J., Du L., Puissant D. The effects of a high-fat, high-fructose, and combination diet on learning, weight, and glucose regulation in C57BL/6 mice. Behav Brain Res. 2007 ; 178 (1). 139-145.
37. Chu KY, Lau T., Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 2006 ; 55 (2). 367-374.
38. Carnethon MR, Prineas RJ, Temprosa M., Zhang ZM, Uwaifo G., Molitch ME The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006 ; 29 (4). 914-919.
39. Malliani A., Pagani M., Lombardi F., Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation. 1991 ; 84: 482-492.
40. Ziegler D., Laude D., Akila F., Elghozi JL Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. Clin Auton Res. 2001 ; 11 (6). 369-376.
41. Stauss HM Power spectral analysis in mice: what are the appropriate frequency bands? Am J Physiol Regul Integr Comp Physiol. 2007 ; 292 (2). R902 - R903.
42. Ponchon P., Elghozi JL Contribution of the renin-angiotensin and kallikrein-kinin systems to short-term variability of blood pressure in two-kidney, one-clip hypertensive rats. Eur J Pharmacol. 1996 ; 297 (1-2). 61-70. (Pubitemid 26062146)
43. Schroeder EB, Chambless LE, Liao D., et al. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2005 ; 28 (3). 668-674.
44. Iyer SN, Raizada MK, Katovich MJ AT1 receptor density changes during development of hypertension in hyperinsulinemic rats. Clin Exp Hypertens. 1996 ; 18 (6). 793-810.
45. Tikellis C., Cooper ME, Bialkowski K., et al. Developmental expression of ACE2 in the SHR kidney: a role in hypertension ? Kidney Int. 2006 ; 70 (1). 34-41.
46. Moon JY, Jeong KH, Lee SH, Lee TW, Ihm CG, Lim SJ Renal ACE and ACE2 expression in early diabetic rats. Nephron Exp Nephrol. 2008 ; 110 (1). e8 - e16.
47. Wei SG, Yu Y., Zhang ZH, Felder RB Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogenactivated protein kinase pathway. Am J Physiol Heart Circ Physiol. 2009 ; 296 (5). H1425 - H1433.
48. Li N., Zimpelmann J., Cheng K., Wilkins JA, Burns KD The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules1. Am J Physiol Renal Physiol. 2005 ; 288 (2). F353 - F362.
49. Alcorn D., McCausland JE, Maric C. Angiotensin receptors and development: the kidney. Clin Exp Pharmacol Physiol Suppl. 1996 ; 3: S88 - S92.
50. Miyazaki M., Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci. 2006 ; 100 (5). 391-397.
51. Ferrario CM, Jessup J., Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005 ; 68 (5). 2189-2196.